European Medicines Agency Recommends New Pancreatic Cancer Therapy

The European Medicines Agency's CHMP has issued a positive opinion for Rasonque (daraxonrasib) as a monotherapy for adults with metastatic pancreatic adenocarcinoma who have undergone at least one prior systemic therapy. This recommendation, if approved by the European Commission, would introduce the first comprehensive RAS-targeted treatment for this challenging cancer in the EU, potentially offering a new option for patients.